[Special Stock] Celltrion Rises Despite KOSPI's Over 3% Decline

[Asia Economy Reporter Park Jihwan] Celltrion is showing a solitary upward trend in the KOSPI market, which fell by over 3% due to the impact of the US stock market plummeting amid concerns of a resurgence of the novel coronavirus infection (COVID-19).

At 9:09 AM on the day, Celltrion was traded at 293,500 KRW, up 5,500 KRW (1.91%) from the previous day on the Korea Exchange. The news that Celltrion Healthcare has started a study to confirm the COVID-19 treatment effect of the biosimilar (biopharmaceutical generic drug) 'Remsima' seems to have influenced this. At this time, among the top 10 KOSPI market capitalization stocks, Celltrion is the only stock showing an increase.

Leading KOSDAQ stock Celltrion Healthcare also rose 400 KRW (0.38%) to 105,400 KRW.

This content was produced with the assistance of AI translation services.